Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD） (NCT06918145) | Clinical Trial Compass
By InvitationNot Applicable
Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD）
China80 participantsStarted 2025-04-02
Plain-language summary
The goal of this clinical trial is to explore the safety and efficacy of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD). The main questions it aims to answer are:
1. After LVA surgery treatment, do patients with AD show improvement in dementia, cognitive impairment, neurobehavioral symptoms?
2. What are the complications associated with LVA treatment for AD, including perioperative complications and long-term complications?
3. What is the mechanism of LVA treatment for AD patients, and what changes occur in AD-related biomarkers (Aβ42、 Aβ40、Aβ42/40、pTau217、pTau181) before and after surgery?
Who can participate
Age range50 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients diagnosed with Alzheimer's Disease based on biomarkers, imaging, and clinical symptoms;
✓. Male or female aged 50-85 years (inclusive);
✓. At least one caregiver who can live with the patient for an extended period;
✓. No severe systemic diseases affecting the heart, liver, kidneys, etc.;
✓. Patients who voluntarily participate in clinical recruitment, accept the LVA surgical treatment plan, and sign the informed consent form.
Exclusion criteria
✕. Poor overall health, unable to tolerate surgery;
✕. Preoperative anesthetic assessment indicates inability to tolerate general anesthesia;
✕. Presence of other neurological or psychiatric disorders;
✕. Severe bleeding tendency due to coagulopathy;
✕. Inability to comply with treatment and follow-up;
What they're measuring
1
The assessment of score changes after Lymphaticovenous Anastomosis(LVA) for the treatment of Alzheimer's Disease(AD) using Mini-Mental State Examination(MMSE).
Timeframe: From enrollment to the end of treatment at 3 days, 7 days, 1 month, 3 months, 6 months,1 year, 3 years, 5 years.